Skip to main content
K

KOMIPHARM INTERNATIONAL CO., LTD. — Investor Relations & Filings

Ticker · 041960 ISIN · KR7041960006 KO Manufacturing
Filings indexed 325 across all filing types
Latest filing 2025-11-07 Regulatory Filings
Country KR South Korea
Listing KO 041960

About KOMIPHARM INTERNATIONAL CO., LTD.

https://komipharm.co.kr/en/

Komipharm International Co., Ltd. is a biopharmaceutical company engaged in the development, manufacturing, and sale of products for both animal and human health. Its Animal Health Division provides a portfolio of veterinary vaccines, pharmaceuticals, and disinfectants. The company's Pharmaceutical Division is dedicated to the research and development of novel therapeutic agents, with key research areas including anticancer drugs and treatments for cancer-related pain and autoimmune diseases. Leveraging extensive experience, the company focuses on intensive R&D to expand its presence in the global bio-industry.

Recent filings

Filing Released Lang Actions
전환가액의조정
Regulatory Filings
2025-11-07 Korean
주요사항보고서(자기주식취득결정)
Regulatory Filings
2025-11-05 Korean
단일판매ㆍ공급계약체결
Regulatory Filings
2025-10-14 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings
2025-09-30 Korean
자기주식취득결과보고서
Regulatory Filings
2025-09-22 Korean
[기재정정]주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically by Susung Asset Management regarding Komipharm) and includes specific sections for reporting changes in shareholding, potential shares (convertible bonds), and transaction details. This falls under the category of Major Shareholding Notification (MRQ).
2025-09-15 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.